Medical School · Year 2 · Immunology · includes a quiz and discussion video

Lecture 3: B Cells and Antibodies

Unit 2.7: Immunology

Learning Objectives

By the end of this lecture, students will be able to:

1. Describe B cell development and activation
2. Explain antibody structure and classes
3. Describe the mechanisms of antibody diversity
4. Explain B cell activation and the germinal center reaction
5. Describe antibody effector functions
6. Explain clinical applications of antibodies

Lecture Outline

I. B Cell Development

B lymphocyte development occurs within the bone marrow microenvironment, where hematopoietic stem cells undergo a carefully orchestrated differentiation program that generates mature B cells capable of responding to foreign antigens while remaining tolerant to self. This developmental process depends on signals from bone marrow stromal cells, which provide essential growth factors including IL-7, and involves progressive immunoglobulin gene rearrangement that ultimately generates the unique B cell receptor defining each clone's antigen specificity. The developmental stages are defined by surface markers, intracellular proteins, and the status of immunoglobulin gene rearrangement.

The earliest committed B cell progenitor, the pro-B cell, expresses CD19 (a pan-B cell marker) but lacks surface immunoglobulin. Pro-B cells initiate heavy chain gene rearrangement through a process requiring the recombination-activating genes RAG1 and RAG2, which recognize recombination signal sequences flanking the V, D, and J gene segments. Rearrangement proceeds in an ordered fashion: D-J joining occurs first, followed by V to DJ joining, generating a complete variable region exon. Successful productive rearrangement of one heavy chain allele triggers allelic exclusion, silencing the second allele to ensure that each B cell expresses only one heavy chain specificity and therefore recognizes only one antigen.

The pre-B cell stage is defined by expression of the pre-B cell receptor, a complex of the newly generated μ heavy chain paired with surrogate light chain components (VpreB and λ5) and the signaling molecules Igα and Igβ. Pre-BCR signaling serves multiple functions: it confirms successful heavy chain rearrangement, triggers cellular proliferation that expands the clone, inhibits further heavy chain rearrangement (enforcing allelic exclusion), and initiates light chain gene rearrangement. Light chain rearrangement involves V-J joining only (no D segments), proceeding first at the κ locus and only attempting λ rearrangement if both κ alleles fail. This results in isotype exclusion, with each B cell expressing either κ or λ but not both.

Central tolerance checkpoints at the immature B cell stage test for self-reactivity and eliminate or edit potentially autoreactive clones. Immature B cells expressing complete surface IgM undergo testing against self-antigens in the bone marrow environment. Strong self-antigen recognition triggers one of three fates: receptor editing (continued light chain rearrangement to change specificity), clonal deletion (apoptosis), or anergy (functional inactivation with survival but reduced responsiveness). Cells that pass this checkpoint mature further, co-expressing IgD with IgM through alternative splicing, and exit to the periphery as mature naive B cells ready to encounter foreign antigen in secondary lymphoid organs.

<image> Panel A: Flowchart of B cell developmental stages in bone marrow showing pro-B (CD19+, heavy chain D-J then V-DJ rearrangement), pre-B (pre-BCR with surrogate light chain, light chain rearrangement), immature B (surface IgM, tolerance checkpoint), and mature naive B (IgM+IgD+, exits to periphery), with RAG expression and key markers at each stage Panel B: Diagram of immunoglobulin heavy chain locus showing multiple V segments, D segments, and J segments with recombination signal sequences, illustrating D-J joining followed by V-DJ joining, looping out and deletion of intervening DNA, and joining to constant region exons Panel C: Pre-BCR complex structure showing μ heavy chain paired with VpreB and λ5 (surrogate light chain components), associated with Igα/Igβ signaling heterodimer containing ITAMs, and downstream signaling promoting proliferation and light chain rearrangement Panel D: Central tolerance outcomes at immature B cell stage showing three fates for self-reactive cells: receptor editing (new light chain changes specificity), deletion (apoptosis), and anergy (survival with functional impairment), versus maturation of non-self-reactive cells </image>

II. Antibody Structure

Antibodies are Y-shaped glycoproteins composed of two identical heavy chains and two identical light chains, linked by disulfide bonds to form a symmetric molecule with two antigen-binding sites. This basic structural unit, the immunoglobulin monomer, weighs approximately 150 kDa for IgG, the most common serum antibody. The Y shape provides functional duality: the two arms (Fab regions) bind antigen while the stem (Fc region) mediates effector functions by interacting with Fc receptors on immune cells and with complement components.

Each antibody chain consists of repeated immunoglobulin domains of approximately 110 amino acids folded into a characteristic β-sandwich structure called the immunoglobulin fold. Heavy chains contain one variable domain (VH) at the N-terminus followed by three or four constant domains (CH1, CH2, CH3, and CH4 for some isotypes). Light chains contain one variable domain (VL) and one constant domain (CL). The variable domains of heavy and light chains pair to create the antigen-binding site, with the constant domains determining the antibody's class and effector functions. A flexible hinge region between CH1 and CH2 in many isotypes allows the Fab arms to move independently, enabling bivalent binding to antigens.

Within the variable domains, sequence variability is concentrated in three hypervariable regions called complementarity-determining regions (CDRs), which form loops at the domain's end that directly contact antigen. CDR1, CDR2, and CDR3 from both VH and VL contribute to the antigen-binding site, with CDR3 being the most variable because it spans the V(D)J junction where junctional diversity mechanisms operate. The framework regions between CDRs maintain the structural scaffold that positions the CDR loops correctly. The CDR loops form a surface complementary in shape and chemistry to the antigenic epitope, enabling high-affinity, specific binding through multiple non-covalent interactions including hydrogen bonds, electrostatic forces, van der Waals interactions, and hydrophobic contacts.

Enzymatic digestion of antibodies reveals their functional domains. Papain cleaves in the hinge region, producing two identical Fab fragments (each containing one antigen-binding site) and one Fc fragment. Pepsin cleaves below the hinge disulfide bonds, generating an F(ab')2 fragment that retains both antigen-binding sites linked by disulfides, useful for applications where Fc-mediated functions are undesirable. Understanding these fragments has been essential for developing therapeutic applications, from using F(ab')2 preparations to avoid Fc-mediated side effects to engineering Fc modifications that enhance or diminish specific effector functions.

<image> Panel A: Complete antibody structure diagram showing Y-shaped molecule with two heavy chains (different colors marking VH, CH1, CH2, CH3 domains) and two light chains (VL and CL domains), disulfide bonds linking chains, hinge region, and Fab versus Fc portions labeled Panel B: Close-up of antigen-binding site showing VH and VL domains paired, with CDR1, CDR2, and CDR3 loops from each chain forming the combining site, antigen (epitope) binding in pocket, and framework regions providing structural support Panel C: Immunoglobulin domain structure showing β-sandwich fold with two β-sheets connected by a disulfide bond, characteristic immunoglobulin fold found in all Ig superfamily members Panel D: Enzyme digestion products showing papain cleavage producing 2 Fab + 1 Fc fragments, pepsin cleavage producing F(ab')2 + degraded Fc, with fragment sizes and clinical applications indicated </image>

III. Antibody Classes (Isotypes)

The five antibody classes—IgM, IgD, IgG, IgA, and IgE—are defined by their heavy chain constant regions (μ, δ, γ, α, and ε, respectively), which determine their effector functions, tissue distribution, and serum half-life. Each class serves distinct roles in immune defense, with some classes further divided into subclasses that provide additional functional specialization. Class switch recombination allows activated B cells to change from IgM production to other classes while maintaining the same antigen specificity, adapting antibody function to the needs of the immune response.

IgM is the first antibody produced during development (as surface BCR) and the first secreted during primary immune responses. Secreted IgM exists as a pentamer of five immunoglobulin units joined by the J chain and disulfide bonds, creating ten antigen-binding sites that compensate for the relatively low affinity of unmutated variable regions. The pentameric structure makes IgM exceptionally efficient at activating complement through the classical pathway, as a single pentamer bound to antigen exposes multiple C1q binding sites. IgM's large size restricts it primarily to the intravascular compartment, where it provides early defense against bloodborne pathogens.

IgG is the most abundant serum immunoglobulin and the predominant antibody of secondary responses, reflecting class switching and affinity maturation in germinal centers. The four IgG subclasses (IgG1-4 in humans) differ in their hinge regions and ability to activate complement and bind Fc receptors. IgG1 and IgG3 are the most effective at complement activation and Fc receptor binding, while IgG4 has anti-inflammatory properties and does not fix complement. IgG is the only antibody class that crosses the placenta via the neonatal Fc receptor (FcRn), providing passive immunity to neonates for the first months of life. FcRn also rescues IgG from lysosomal degradation, explaining IgG's uniquely long half-life of approximately 21 days.

IgA dominates mucosal surfaces as the body's most abundantly produced antibody class. Secretory IgA (sIgA) is a dimer linked by J chain with an additional secretory component acquired during transcytosis across epithelial cells. The secretory component protects IgA from proteolytic degradation in harsh mucosal environments. sIgA functions primarily through immune exclusion, neutralizing pathogens and toxins in the mucosal lumen before they can cross the epithelial barrier. IgE, though present at the lowest serum concentration, plays crucial roles in defense against helminth parasites and in allergic diseases. IgE binds with extremely high affinity to FcεRI on mast cells and basophils, remaining bound for weeks and sensitizing these cells for immediate degranulation upon antigen encounter.

<image> Panel A: Structural comparison of antibody classes showing IgG monomer, IgM pentamer with J chain, secretory IgA dimer with J chain and secretory component, IgE monomer with extra CH domain, and IgD monomer, with molecular weights indicated Panel B: IgG subclass comparison table showing IgG1-4 with relative serum concentrations, complement fixation ability, FcR binding, placental transfer, and half-lives, highlighting functional differences between subclasses Panel C: Secretory IgA pathway showing plasma cell producing dimeric IgA in lamina propria, poly-Ig receptor on basolateral epithelial surface binding J chain, transcytosis across epithelium, cleavage releasing sIgA with attached secretory component into lumen Panel D: IgE-mast cell interaction showing high-affinity FcεRI binding IgE Fc, IgE remaining bound for extended periods, and antigen crosslinking of surface IgE triggering degranulation with histamine release, plus basophil recruitment in allergic response </image>

IV. B Cell Activation

B cell activation occurs through two distinct pathways depending on the nature of the antigen and the requirement for T cell help. T-independent antigens can activate B cells without T cell assistance, while T-dependent antigens require cognate T cell help for full B cell activation, class switching, and affinity maturation. The type of activation pathway determines the quality and duration of the antibody response, with T-dependent responses generally producing more effective, longer-lasting immunity.

T-independent (TI) antigens are classified into two types based on their mechanism of B cell activation. TI-1 antigens, exemplified by bacterial lipopolysaccharide, activate B cells through pattern recognition receptors (particularly TLRs) in addition to BCR engagement, providing the second signal needed for activation. TI-2 antigens, such as bacterial capsular polysaccharides, consist of highly repetitive structures that extensively crosslink BCRs, providing a strong activation signal through receptor clustering alone. TI responses generate predominantly IgM antibodies with limited class switching and no affinity maturation, producing rapid but relatively weak protection. Memory generation is also limited, explaining why polysaccharide vaccines provide short-lived immunity, particularly in young children whose B cells respond poorly to TI-2 antigens.

T-dependent (TD) activation begins when B cells recognize protein antigens through their BCR, internalize the antigen, process it through the endosomal pathway, and present peptide fragments on MHC class II molecules. This allows B cells to receive help from CD4+ T follicular helper (Tfh) cells that recognize the same antigen (linked recognition). The B cell-T cell interaction occurs at the border between B cell follicles and T cell zones in secondary lymphoid organs, where activated Tfh cells provide critical signals through CD40 ligand (CD40L) binding to CD40 on B cells, and through cytokines including IL-4 and IL-21 that direct class switching and plasma cell differentiation.

Following initial activation, B cells can pursue two distinct fates. Some rapidly differentiate into short-lived plasma cells in extrafollicular sites, providing an early wave of predominantly IgM antibodies within days of infection. Others enter B cell follicles to establish germinal centers, specialized microanatomical structures where B cells undergo proliferation, somatic hypermutation, and selection for improved antigen binding. The germinal center reaction generates high-affinity, class-switched memory B cells and long-lived plasma cells that provide durable protection. The decision between these fates depends on signal strength, T cell help availability, and B cell-intrinsic factors.

<image> Panel A: Comparison of T-independent and T-dependent B cell activation showing TI-1 (LPS engaging TLR4 + BCR), TI-2 (polysaccharide extensive BCR crosslinking), and TD (BCR internalization, processing, MHC II presentation to Tfh), with outcomes for each pathway Panel B: Cognate B cell-Tfh cell interaction showing B cell presenting processed antigen on MHC II to Tfh TCR, CD40-CD40L costimulation, and cytokine signals (IL-4, IL-21) directing B cell activation and class switch, occurring at T-B border zone Panel C: B cell fate decision diagram showing activated B cell either becoming short-lived extrafollicular plasma cell (rapid IgM, days to weeks survival) or entering germinal center (proliferation, SHM, selection, generating memory B cells and long-lived plasma cells) Panel D: Timeline of antibody response showing early extrafollicular response (days 3-7, mainly IgM) and later germinal center-derived response (weeks 2-4, class-switched, high-affinity), with memory establishment </image>

V. Germinal Center Reaction

Germinal centers are specialized microstructures that form within B cell follicles during T-dependent immune responses, providing the environment for B cell clonal expansion, somatic hypermutation, and selection for improved antigen binding. These dynamic structures appear approximately one week after antigen exposure and can persist for weeks to months depending on antigen availability and the immune response's requirements. The germinal center reaction is essential for generating high-affinity antibodies and long-lived immunological memory.

The germinal center is organized into two functionally distinct zones. The dark zone, named for its densely packed appearance on histological sections, contains rapidly proliferating B cells called centroblasts. Centroblasts undergo somatic hypermutation (SHM), a process mediated by activation-induced cytidine deaminase (AID) that introduces point mutations throughout the variable region genes encoding the antigen-binding site. AID deaminates cytidine to uracil in DNA, and the resulting mismatches are processed by error-prone repair pathways that convert them into mutations. The mutation rate during SHM (approximately 10^-3 per base pair per cell division) is about one million times higher than the normal cellular mutation rate.

The light zone contains B cells called centrocytes that have ceased proliferating and are undergoing selection based on the affinity of their mutated BCRs. Follicular dendritic cells (FDCs) in the light zone display intact antigen trapped as immune complexes, providing the ligand against which centrocytes compete. Centrocytes with higher-affinity BCRs capture more antigen, internalize it, and present more peptide-MHC II complexes to limiting numbers of Tfh cells. Tfh cells provide survival signals to centrocytes proportional to the amount of antigen presented, creating a Darwinian selection process that favors B cells with improved antigen binding. Centrocytes receiving insufficient help undergo apoptosis, while selected centrocytes can recycle to the dark zone for further rounds of mutation and selection.

After multiple cycles of mutation and selection, germinal center B cells exit as either memory B cells or long-lived plasma cells. Memory B cells, expressing class-switched, high-affinity BCRs, exit to circulate and reside in secondary lymphoid organs and peripheral tissues, providing rapid responses upon antigen re-encounter. Long-lived plasma cells migrate to bone marrow survival niches where they can persist for years or decades, continuously secreting antibody and maintaining protective serum titers without requiring reactivation. The germinal center reaction thus couples diversification (SHM) with selection (Tfh-mediated) to produce antibodies with progressively higher affinity, a process called affinity maturation.

<image> Panel A: Germinal center architecture showing dark zone (densely packed proliferating centroblasts undergoing SHM) and light zone (FDCs displaying antigen, Tfh cells providing selection signals, centrocytes competing for help), with cycling between zones indicated Panel B: Somatic hypermutation mechanism showing AID targeting variable region DNA, cytidine deamination creating uracil, DNA repair pathways introducing mutations, and resulting point mutations in CDR and framework regions affecting antibody affinity Panel C: Selection in light zone showing centrocyte capturing antigen from FDC, processing and presenting to Tfh cell, receiving survival signals proportional to antigen presentation (more antigen = more help), and fate determination (survival and recycling versus apoptosis) Panel D: Germinal center outputs showing two fates: memory B cells (class-switched, high-affinity BCR, long-lived, peripheral circulation and tissue residence) and long-lived plasma cells (antibody factories, migration to bone marrow niches, decades-long survival) </image>

VI. Class Switch Recombination

Class switch recombination (CSR) is a DNA recombination process that changes the antibody class produced by a B cell while preserving its antigen specificity. This occurs through deletion of DNA between switch (S) regions located upstream of each constant region gene, joining the rearranged VDJ exon to a downstream constant region. CSR requires AID (the same enzyme involved in somatic hypermutation) and occurs primarily in activated B cells receiving appropriate T cell signals, allowing the immune response to deploy different effector functions against the same antigen.

The heavy chain constant region locus contains the μ gene first, followed by δ (which is co-expressed with μ through alternative splicing rather than CSR), then γ3, γ1, α1, γ2, γ4, ε, and α2 in humans. Switch regions preceding each constant gene (except δ) are repetitive GC-rich sequences that serve as targets for AID-induced DNA breaks. AID deaminates cytosines in switch regions of both the donor (Sμ) and acceptor (downstream) switch regions, creating single-strand breaks that are converted to double-strand breaks. The DNA repair machinery then joins the broken ends, looping out and deleting the intervening constant region genes. Because deleted DNA is lost, class switching is irreversible and generally proceeds from μ to downstream constant regions.

Cytokines from helper T cells direct the choice of which constant region will be selected during CSR. IL-4 promotes switching to IgE and IgG4 (IgG1 in mice), appropriate for responses against parasites and in allergic inflammation. Interferon-γ (IFN-γ) promotes switching to IgG1 and IgG3 (IgG2a in mice), the most effective isotypes for complement fixation and Fc receptor-mediated phagocytosis in antibacterial responses. TGF-β promotes switching to IgA, appropriate for mucosal immunity. These cytokines work by making specific switch regions accessible to transcription and AID activity, while other switch regions remain inaccessible.

Defects in CSR cause immunodeficiency characterized by elevated IgM and deficient IgG, IgA, and IgE—the hyper-IgM syndromes. X-linked hyper-IgM syndrome (type 1) results from CD40L mutations that prevent B cells from receiving T cell help signals needed for CSR and germinal center formation. Type 2 hyper-IgM syndrome results from AID mutations that prevent both CSR and SHM. Affected patients suffer from recurrent bacterial infections due to deficient antibody responses, and type 1 patients also have increased susceptibility to opportunistic infections because CD40L is important for macrophage activation. These genetic conditions have been invaluable for understanding CSR mechanisms and the importance of class-switched antibodies in immune defense.

<image> Panel A: Heavy chain constant region locus map showing Sμ, Cμ, Sγ3, Cγ3, Sγ1, Cγ1, etc. arrangement, with VDJ exon upstream, illustrating how CSR deletes intervening genes to bring VDJ adjacent to downstream constant regions Panel B: CSR mechanism diagram showing AID targeting both Sμ and downstream switch region (e.g., Sγ1), creating double-strand breaks, DNA repair machinery joining broken ends, and looping out of intervening DNA Panel C: Cytokine direction of class switching showing IL-4 promoting IgE/IgG4, IFN-γ promoting IgG1/IgG3, TGF-β promoting IgA, with corresponding immune contexts (allergy, bacterial defense, mucosal immunity) Panel D: Hyper-IgM syndromes showing normal versus affected antibody profiles (high IgM, absent IgG/IgA/IgE), genetic causes (CD40L deficiency = type 1, AID deficiency = type 2), and clinical manifestations (bacterial infections, opportunistic infections in type 1) </image>

VII. Antibody Effector Functions

Neutralization represents the simplest antibody effector mechanism, requiring only antigen binding without Fc-dependent functions. Antibodies neutralize pathogens and toxins by physically blocking their interaction with host cell receptors, preventing viral attachment to target cells or toxin binding to cellular substrates. For many viruses, antibodies binding to surface glycoproteins prevent the conformational changes required for membrane fusion and cell entry. For toxins like tetanus and diphtheria toxins, antibodies binding near receptor-binding domains sterically hinder toxin-cell interaction. Neutralization is particularly important at mucosal surfaces, where secretory IgA intercepts pathogens before they can cross the epithelial barrier.

Opsonization enhances phagocytosis by coating pathogens with antibody molecules whose Fc regions are recognized by Fc receptors on phagocytes. IgG is the most effective opsonin, binding to FcγRI, FcγRIIA, and FcγRIII on macrophages, neutrophils, and dendritic cells. Fc receptor engagement delivers activation signals through ITAMs (immunoreceptor tyrosine-based activation motifs), triggering phagocytosis, respiratory burst, and release of inflammatory mediators. Opsonization dramatically increases the efficiency of phagocytosis, particularly for encapsulated bacteria whose polysaccharide capsules otherwise resist phagocyte recognition. The combination of IgG opsonization with C3b deposition (complement-mediated opsonization) provides synergistic enhancement of phagocytosis.

Complement activation by antibodies occurs through the classical pathway when C1q binds to the Fc regions of antigen-bound IgM or IgG. IgM pentamers are particularly efficient complement activators because a single pentamer binding to a surface provides multiple C1q binding sites in close proximity. IgG activates complement less efficiently on a per-molecule basis but can be effective when multiple IgG molecules bind closely on a surface, enabling C1q to bind with multiple heads. Complement activation amplifies antibody-mediated defense through C3b opsonization, generation of chemotactic factors (C3a, C5a), and direct pathogen lysis by the membrane attack complex.

Antibody-dependent cellular cytotoxicity (ADCC) bridges antibody recognition with cellular killing, allowing NK cells to destroy antibody-coated target cells. IgG bound to target cell surface antigens is recognized by FcγRIII (CD16) on NK cells, triggering degranulation and release of perforin and granzymes that induce target cell apoptosis. ADCC is important in defense against some viral infections where antibodies recognize viral proteins on infected cell surfaces, and is a major mechanism of action for therapeutic antibodies targeting tumor cells, including rituximab (anti-CD20 for B cell lymphomas) and trastuzumab (anti-HER2 for breast cancer).

<image> Panel A: Neutralization mechanisms showing antibody binding to virus blocking receptor attachment and entry, and antibody binding to toxin preventing receptor binding, with mucosal IgA preventing pathogen translocation across epithelium Panel B: Opsonization and phagocytosis showing IgG-coated bacterium, FcγR on macrophage binding Fc portions, triggering phagocytosis through ITAM signaling, with complement C3b providing additional opsonization through CR1 Panel C: Classical complement activation by antibody showing IgM pentamer with multiple C1q binding sites, or multiple IgG molecules clustering to recruit C1q, leading to complement cascade activation with C3b deposition, anaphylatoxin release, and MAC formation Panel D: ADCC mechanism showing tumor cell or virus-infected cell coated with IgG, NK cell FcγRIII (CD16) binding IgG Fc, triggering directed degranulation of perforin and granzymes toward target cell, inducing apoptosis </image>

VIII. Fc Receptors

Fc receptors are cell surface molecules that bind the Fc portions of immunoglobulins, transducing signals that trigger effector functions when antibody-antigen complexes engage the receptor. Different Fc receptor families exist for each antibody class, designated by Greek letters (FcγR for IgG, FcεR for IgE, FcαR for IgA), with each family containing multiple members that differ in affinity, cellular distribution, and signaling properties. Fc receptors translate humoral immunity into cellular effector functions, linking antibody recognition to phagocytosis, degranulation, cytokine release, and cytotoxicity.

FcγRI (CD64) is a high-affinity receptor for IgG expressed on macrophages, monocytes, and dendritic cells that can bind monomeric IgG. FcγRIIA and FcγRIIIA are low-affinity receptors that bind IgG only when aggregated in immune complexes, ensuring that cells respond to antibody engaged with target rather than circulating free antibody. These activating receptors contain or associate with ITAMs that recruit kinases like Syk upon receptor crosslinking, initiating signaling cascades that trigger phagocytosis, respiratory burst, and inflammatory mediator release. FcγRIII (CD16) on NK cells mediates ADCC, while FcγRIII on macrophages contributes to immune complex clearance.

FcγRIIB is unique among human FcγRs as the sole inhibitory receptor, containing an ITIM (immunoreceptor tyrosine-based inhibitory motif) rather than ITAMs. When co-ligated with the BCR on B cells, FcγRIIB delivers inhibitory signals that dampen B cell activation, providing negative feedback when antibody concentrations are high. This feedback loop helps terminate immune responses once sufficient antibody has been produced. FcγRIIB on other myeloid cells similarly provides inhibitory signals that balance activating receptor signals. Genetic variants and expression levels of FcγRIIB influence susceptibility to autoimmune diseases, with reduced FcγRIIB function associated with autoantibody production.

The neonatal Fc receptor (FcRn), despite its name, plays important roles throughout life. FcRn binds IgG at acidic pH (as in endosomes) but releases it at neutral pH (as in blood), enabling receptor recycling. In placental syncytiotrophoblasts, FcRn transports maternal IgG across the placenta to the fetus, providing passive immunity in early life. In endothelial and epithelial cells throughout the body, FcRn rescues endocytosed IgG from lysosomal degradation by binding it in endosomes and returning it to the cell surface, explaining IgG's uniquely long serum half-life of approximately 21 days. FcRn is also present at mucosal surfaces where it can transcytose IgG into luminal secretions.

<image> Panel A: FcγR family overview showing FcγRI (high-affinity, macrophages, activating ITAM), FcγRIIA (low-affinity, neutrophils/macrophages, activating ITAM), FcγRIIB (inhibitory ITIM, B cells/macrophages), and FcγRIIIA (NK cells, activating, mediates ADCC), with cellular expression patterns Panel B: Activating versus inhibitory Fc receptor signaling showing ITAM-containing receptor crosslinking leading to Syk recruitment and activation cascades, versus ITIM-containing FcγRIIB recruiting SHP-1 phosphatase to inhibit activation signals Panel C: FcγRIIB negative feedback on B cells showing antibody-antigen complex simultaneously engaging BCR and FcγRIIB, ITIM recruitment of SHP-1, dephosphorylation of activating signals, resulting in dampened B cell activation when antibody levels are high Panel D: FcRn function showing pH-dependent binding (binds at pH 6, releases at pH 7.4), placental IgG transport from maternal to fetal circulation, and IgG rescue from degradation with recycling to plasma, explaining 21-day half-life </image>

IX. Antibody Diversity

The human immune system generates an enormous diversity of antibody specificities, with estimates exceeding 10^11 possible unique binding sites, far greater than the approximately 20,000 protein-coding genes in the human genome. This diversity is achieved through combinatorial mechanisms during V(D)J recombination, junctional diversity at recombination sites, heavy-light chain pairing, and somatic hypermutation after B cell activation. Together, these mechanisms enable the B cell repertoire to recognize virtually any molecular structure, including synthetic compounds never encountered in nature.

Combinatorial diversity arises from the random selection of individual V, D, and J gene segments during heavy chain rearrangement, and V and J segments during light chain rearrangement. The human heavy chain locus contains approximately 40 functional VH genes, 25 DH genes, and 6 JH genes, allowing roughly 6,000 different VDJ combinations. The κ and λ light chain loci together provide approximately 350 possible VJ combinations. The product of heavy and light chain combinations yields approximately 2 × 10^6 possible antibodies from combinatorial diversity alone.

Junctional diversity dramatically expands the repertoire by introducing variability at the precise sites where gene segments join. During V(D)J recombination, the RAG recombinase cleaves DNA at recombination signal sequences, generating hairpin-sealed coding ends. These hairpins are opened asymmetrically by the Artemis nuclease, and exonucleases may remove nucleotides (P-nucleotide addition results from hairpin asymmetric opening). Terminal deoxynucleotidyl transferase (TdT) adds non-templated nucleotides (N-nucleotides) to the ends before joining, introducing sequence that is not encoded in the germline. Because CDR3 spans the VDJ junction, this junctional diversity directly affects the antigen-binding site, greatly expanding the range of antigens that can be recognized.

Somatic hypermutation (SHM) during germinal center reactions introduces additional diversity into already rearranged antibody genes. AID targets the rearranged variable region genes (both heavy and light chains), introducing point mutations at rates approximately one million-fold higher than background mutation rates. Most mutations are neutral or deleterious, but occasional mutations improve antigen binding and are selected through Tfh cell-dependent mechanisms. Multiple rounds of mutation and selection progressively increase antibody affinity, a process called affinity maturation. SHM is unique to B cells among vertebrate somatic cells and is absent from T cells, which do not undergo affinity maturation of their antigen receptors.

<image> Panel A: Sources of antibody diversity illustrated as multiplicative factors: V segment choices × D segment choices × J segment choices × junctional diversity × heavy-light pairing × somatic hypermutation = >10^11 possible specificities Panel B: Junctional diversity mechanisms showing RAG cleavage generating hairpins, asymmetric hairpin opening creating P-nucleotides, exonuclease nibbling removing bases, and TdT adding random N-nucleotides, with resulting junction sequence variability highlighted Panel C: Heavy chain locus calculation showing ~40 VH × ~25 DH × ~6 JH = ~6,000 heavy chain combinations, and light chain ~70 VL × ~5 JL combinations, with heavy × light pairing yielding ~2 × 10^6 combinations from combinatorial diversity alone Panel D: Affinity maturation through SHM showing germinal center B cell with AID-mediated mutation, mutations in CDRs potentially improving affinity, selection favoring higher-affinity variants, and progressive affinity increase over multiple cycles graphed </image>

X. Clinical Applications

Diagnostic applications of antibodies exploit their exquisite specificity for detecting and quantifying antigens and other antibodies. Enzyme-linked immunosorbent assays (ELISAs) use antibodies bound to surfaces to capture target molecules, with detection by enzyme-conjugated secondary antibodies producing colorimetric, fluorescent, or luminescent signals. Serology, the detection of pathogen-specific antibodies in patient serum, provides evidence of current or past infection; IgM detection suggests acute infection, while IgG indicates prior exposure or chronic infection. Western blotting uses antibodies to detect specific proteins separated by electrophoresis, while immunohistochemistry visualizes antigen distribution in tissue sections for pathological diagnosis.

Therapeutic monoclonal antibodies represent one of the fastest-growing classes of pharmaceuticals, with applications spanning oncology, autoimmunity, infectious diseases, and beyond. Monoclonal antibody technology, developed by Köhler and Milstein in 1975, generates unlimited supplies of identical antibodies with defined specificity. Modern therapeutic antibodies are typically chimeric (mouse variable regions fused to human constant regions, suffix -ximab), humanized (mouse CDRs grafted onto human framework, suffix -zumab), or fully human (derived from transgenic mice or phage display, suffix -umab), reducing immunogenicity compared to purely murine antibodies (-omab).

Mechanism-based applications include antibodies that deplete specific cell populations (rituximab targeting CD20 on B cells for lymphoma and autoimmune diseases), block signaling pathways (trastuzumab targeting HER2 in breast cancer), neutralize cytokines (anti-TNF agents for inflammatory diseases), or interfere with immune checkpoints (pembrolizumab targeting PD-1 for cancer immunotherapy). Fc engineering modifies effector functions, with some antibodies designed to enhance ADCC for tumor killing and others designed with reduced Fc function to minimize inflammatory side effects. Bispecific antibodies simultaneously bind two different targets, enabling applications like T cell redirectors that link tumor antigens to CD3 on T cells.

Intravenous immunoglobulin (IVIG), prepared from pooled plasma of thousands of donors, provides both replacement therapy for antibody deficiencies and immunomodulation for autoimmune and inflammatory conditions. In replacement therapy, IVIG substitutes for absent or deficient antibodies in primary immunodeficiencies like X-linked agammaglobulinemia and common variable immunodeficiency. Immunomodulatory applications, using higher doses, include immune thrombocytopenia, Kawasaki disease, Guillain-Barré syndrome, and chronic inflammatory demyelinating polyneuropathy. Mechanisms of immunomodulation include FcγRIIB engagement, Fc receptor saturation, anti-idiotype interactions, and complement scavenging, though the precise mechanisms vary by condition.

<image> Panel A: ELISA formats showing direct ELISA (antigen captured, enzyme-conjugated antibody detection), sandwich ELISA (capture antibody, antigen, detection antibody), and competitive ELISA, with applications in diagnostics (pathogen detection, antibody quantification, hormone assays) Panel B: Therapeutic antibody nomenclature showing evolution from murine (-omab) to chimeric (-ximab, mouse V + human C) to humanized (-zumab, mouse CDRs in human framework) to fully human (-umab), with decreasing immunogenicity Panel C: Therapeutic antibody mechanisms showing direct action (blocking receptors, neutralizing cytokines), cell depletion (CDC, ADCC, phagocytosis after opsonization), and immune checkpoint blockade (releasing T cell brakes), with example drugs for each Panel D: IVIG applications showing replacement therapy (providing antibodies for immunodeficient patients) and immunomodulation (high-dose treatment for ITP, Kawasaki, CIDP), with proposed mechanisms of immunomodulation (FcγRIIB engagement, Fc receptor saturation, anti-idiotypes) </image>

Summary

• B cell development in bone marrow proceeds through pro-B, pre-B, immature, and mature stages with progressive Ig gene rearrangement
• Central tolerance eliminates or edits self-reactive B cells through receptor editing, deletion, or anergy
• Antibodies are Y-shaped molecules with two Fab regions for antigen binding and one Fc region for effector functions
• Five antibody classes (IgM, IgD, IgG, IgA, IgE) provide distinct effector functions and tissue distributions
• T-dependent activation requires Tfh cell help and enables class switching and affinity maturation
• Germinal centers are sites of B cell proliferation, somatic hypermutation, and selection for high-affinity clones
• Class switch recombination, directed by cytokines, changes antibody class while preserving antigen specificity
• Antibody effector functions include neutralization, opsonization, complement activation, and ADCC
• Diversity exceeding 10^11 specificities arises from V(D)J recombination, junctional diversity, and somatic hypermutation
• Clinical applications include diagnostics (ELISA, serology), therapeutic monoclonal antibodies, and IVIG

Key Terms

This content is subject to the MIT License. © 2024–2026 Hibbert School of Medicine.

Read this lecture as Markdown